139 related articles for article (PubMed ID: 29844693)
1. Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.
Pollock RF; Chubb B; Valentine WJ; Heller S
Diabetes Metab Syndr Obes; 2018; 11():217-226. PubMed ID: 29844693
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain.
Morales C; de Luis D; de Arellano AR; Ferrario MG; Lizán L
Diabetes Ther; 2015 Dec; 6(4):593-610. PubMed ID: 26589521
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
[TBL] [Abstract][Full Text] [Related]
6. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
Valentine WJ; Jendle J; Saraheimo M; Thorsteinsson B; Pollock RF; Lammert M
Diabet Med; 2012 Mar; 29(3):303-12. PubMed ID: 21951030
[TBL] [Abstract][Full Text] [Related]
8. Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis.
Dawoud D; Fenu E; Higgins B; Wonderling D; Amiel SA
Value Health; 2017 Dec; 20(10):1279-1287. PubMed ID: 29241887
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
[TBL] [Abstract][Full Text] [Related]
10. Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study.
Ji J; He Z; Yang Z; Mi Y; Guo N; Zhao H; Gao J; Ma Z; Luo X; Han Z
BMJ Open Diabetes Res Care; 2020 Apr; 8(1):. PubMed ID: 32265255
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of insulin detemir: a systematic review.
Suh DC; Aagren M
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):641-55. PubMed ID: 21961796
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
Gschwend MH; Aagren M; Valentine WJ
J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis.
Lau E; Salem A; Chan JCN; So WY; Kong A; Lamotte M; Luk A
Cost Eff Resour Alloc; 2019; 17():13. PubMed ID: 31303866
[TBL] [Abstract][Full Text] [Related]
15. Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia.
Pedersen-Bjergaard U; Kristensen PL; Nørgaard K; Perrild H; Jensen T; Thorsteinsson B; Nikolajsen A; Tarnow L
Curr Med Res Opin; 2016 Oct; 32(10):1719-1725. PubMed ID: 27326862
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A1chieve study.
Wangnoo SK; Ghosal S; Akhtar S; Shetty R; Tripathi S
Indian J Endocrinol Metab; 2014 Sep; 18(5):715-20. PubMed ID: 25285292
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
Valentine WJ; Palmer AJ; Erny-Albrecht KM; Ray JA; Cobden D; Foos V; Lurati FM; Roze S
Adv Ther; 2006; 23(2):191-207. PubMed ID: 16751153
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes.
Herrera KM; Rosenn BM; Foroutan J; Bimson BE; Al Ibraheemi Z; Moshier EL; Brustman LE
Am J Obstet Gynecol; 2015 Sep; 213(3):426.e1-7. PubMed ID: 26070699
[TBL] [Abstract][Full Text] [Related]
19. Costs associated with long-acting insulin analogues in patients with diabetes.
Alemayehu B; Speiser J; Bloudek L; Sarnes E
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP265-SP272. PubMed ID: 30020738
[TBL] [Abstract][Full Text] [Related]
20. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
